Necitumumab (11F8) (Ly3012211)


Combined with:

Cisplatin

Indications and Reactions:

Role Indications Reactions
Primary
Non-small Cell Lung Cancer 24.7%
Pain 10.3%
Chronic Obstructive Pulmonary Disease 6.8%
Non-small Cell Lung Cancer Stage Iv 6.2%
Rash 6.2%
Nausea 5.5%
Constipation 4.8%
Prophylaxis 4.8%
Asthma 4.1%
Neoplasm Malignant 4.1%
Premedication 4.1%
Dyspnoea 2.7%
Hypertension 2.7%
Arteriosclerosis Obliterans 2.1%
Diabetes Mellitus 2.1%
Insomnia 2.1%
Neoplasm 2.1%
Ovarian Cancer Metastatic 2.1%
Chest Pain 1.4%
Cough 1.4%
Haemoptysis 12.5%
General Physical Health Deterioration 8.3%
Pneumonia 8.3%
Renal Failure Acute 8.3%
Acute Myocardial Infarction 4.2%
Cerebral Ischaemia 4.2%
Coronary Artery Disease 4.2%
Dehydration 4.2%
Duodenal Ulcer Haemorrhage 4.2%
Hypomagnesaemia 4.2%
Hypophagia 4.2%
Ischaemic Stroke 4.2%
Lower Respiratory Tract Infection 4.2%
Malaise 4.2%
Myocardial Infarction 4.2%
Peripheral Ischaemia 4.2%
Renal Failure 4.2%
Renal Infarct 4.2%
Thrombocytopenia 4.2%
Secondary
Non-small Cell Lung Cancer 39.1%
Non-small Cell Lung Cancer Stage Iv 12.3%
Pain 5.7%
Chronic Obstructive Pulmonary Disease 5.3%
Prophylaxis 4.8%
Nausea 4.4%
Constipation 4.3%
Hypertension 4.2%
Rash 2.8%
Chest Pain 2.6%
Product Used For Unknown Indication 2.2%
Mucosal Inflammation 2.0%
Mouth Ulceration 1.8%
Dyspnoea 1.7%
Medical Diet 1.7%
Hypokalaemia 1.5%
Hypertonia 1.1%
Productive Cough 0.9%
Sedation 0.9%
Cough 0.8%
Pulmonary Embolism 17.6%
Death 6.7%
Intestinal Perforation 5.9%
Oesophageal Ulcer 5.9%
Pneumonia 5.9%
Thrombocytopenia 5.9%
Dehydration 5.0%
Thrombosis 5.0%
Vomiting 5.0%
Convulsion 4.2%
Deep Vein Thrombosis 4.2%
General Physical Health Deterioration 4.2%
Haemoptysis 4.2%
Brain Oedema 3.4%
Haemorrhage 3.4%
Venous Thrombosis Limb 3.4%
Blood Phosphorus Decreased 2.5%
Bronchitis 2.5%
Neutropenia 2.5%
Pancytopenia 2.5%

Drug Data